Clinical trials
Lupus clinical trials
Below are recruiting lupus clinical trials, each written for real people, not researchers. We’re tracking 338 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07107659RecruitingEarly Phase 1
Testing ONT01 for active lupus
This trial tests a new drug called ONT01 for people with active lupus that is not affecting their kidneys. It is for those who have not had success with standard treatments.
New York, New YorkAges 18 years+ - NCT07570862RecruitingPhase 2
CAR T-Cell Therapy for Hard-to-Treat Lupus Kidney Disease
This trial tests FT819, a new type of immune cell therapy (CAR T cells), for people with lupus nephritis—kidney inflammation caused by lupus—who haven't responded well to standard treatments. The goal is to see if this therapy can reduce kidney damage and improve kidney function.
Beverly Hills, CaliforniaAges 12–70 - NCT07598396RecruitingPhase 2
Mosunetuzumab for systemic lupus erythematosus treatment
This study tests a new drug called mosunetuzumab in people with systemic lupus erythematosus (SLE), a disease where the immune system attacks the body's own tissues. The drug is designed to help control the immune response and reduce lupus symptoms, including kidney involvement if present.
Salvador, Estado de BahiaAges 18 years+ - NCT07260877RecruitingPhase 2
Testing VENT-03 for active skin lupus with or without systemic lupus
This study tests an experimental medicine called VENT-03 to see if it can improve skin lupus symptoms in adults. It compares VENT-03 against a placebo (a pill with no active drug) and includes a longer-term option where everyone can get the real drug. The goal is to find a new treatment for people whose lupus affects their skin.
Beverly Hills, CaliforniaAges 18–80 - NCT05934149Recruiting
Lupus health registry that stores samples for future research
This study keeps a long-term record of people with lupus (systemic lupus erythematosus) and collects samples so researchers can study the disease better. You may be able to join if you meet lupus diagnosis criteria, are not pregnant, and can follow the study visits and consent process.
Birmingham, AlabamaAges 18–110 - NCT06737380RecruitingPhase 1
Stem Cell Therapy Study for Active Lupus
This study tests whether a special type of stem cell treatment (called UC-MSC) can help calm lupus when standard medicines aren't enough. It's for people with active lupus who have tried other non-steroid medications.
Charleston, South CarolinaAges 18–75 - NCT06927219Recruiting
Lupus registry for patients and caregivers
This study creates a registry for people with lupus and their families. It helps researchers learn more about lupus and improve care. You or your child can join if you have a lupus diagnosis.
Washington D.C., District of ColumbiaAges Any age - NCT06581198RecruitingPhase 2
CAR-T cell therapy for lupus or lupus nephritis
This trial tests a new CAR-T cell treatment called rapcabtagene autoleucel for people with active lupus or lupus nephritis that hasn't improved with at least two standard therapies. It aims to reduce disease activity and may offer a new option for hard-to-treat cases.
Birmingham, AlabamaAges 18–75 - NCT06839976RecruitingPhase 1/Phase 2
CART19 cell therapy for lupus in young people
This trial tests whether a special type of immune cell, called CART19, can help young people with active lupus that hasn't gotten better with standard treatments. If you join, doctors will take some of your blood cells, modify them to attack lupus-causing cells, and then give them back to you.
Philadelphia, PennsylvaniaAges 12–29 - NCT06875960RecruitingPhase 4
Continuing deucravacitinib for people with lupus
This study lets people who have already finished a previous trial of deucravacitinib continue taking the medicine. It is for adults with lupus, including skin-only forms of the disease, to see if long-term treatment remains safe and helpful.
Farmington, ConnecticutAges 18–75 - NCT07109986RecruitingPhase 1
Study of UB-VV410 for active lupus or lupus nephritis
This trial tests a new treatment, UB-VV410, for people with active systemic lupus erythematosus (SLE) or lupus nephritis (kidney inflammation caused by lupus) that hasn't responded to standard treatments. It aims to see if this therapy can help control the disease.
NanjingAges 18–65 - NCT07491900RecruitingPhase 1
Study of HB2198 for lupus with moderate to severe symptoms
This trial tests a new drug called HB2198 to see if it can help people with moderate to severe lupus. It may be an option for those whose current treatments haven't worked well enough.
BrisbaneAges 18–65 - NCT07053800RecruitingPhase 2
Obe-cel for severe lupus with kidney inflammation
This trial tests a new cell therapy called obe-cel in people ages 12 to 65 with severe systemic lupus erythematosus (SLE) that has not responded to other treatments and has caused active lupus nephritis (kidney disease). The goal is to see if obe-cel can reduce lupus activity and improve kidney health.
New York, New YorkAges 12–65 - NCT03673748RecruitingPhase 2
Mesenchymal stem cell treatment for lupus kidney inflammation
This trial tests whether donated (allogeneic) stem cells can improve lupus nephritis, a kidney complication of lupus. It is for adults whose lupus kidney disease has not responded well to standard treatments or has come back, and it requires signs of active disease.
Valladolid, ValladolidAges 18 years+ - NCT07355218RecruitingPhase 3
Testing enpatoran for lupus skin problems
This trial tests an oral drug called enpatoran for people with lupus that causes skin rashes (like discoid or subacute cutaneous lupus). The goal is to see if the drug can improve these skin symptoms.
Upland, CaliforniaAges 18–75 - NCT07332481RecruitingPhase 3
Testing enpatoran for lupus affecting the skin
This trial tests if a drug called enpatoran can help people with lupus that causes skin rashes, like discoid lupus or subacute cutaneous lupus. It may be for those with or without systemic lupus.
Los Angeles, CaliforniaAges 18–75 - NCT07760480RecruitingPhase 4
Intensified treatment for lupus nephritis
This study tests whether adding a drug called voclosporin to the usual treatment for lupus nephritis (a kidney disease caused by lupus) can better reduce kidney inflammation. It also looks at the role of immune cells in this process.
AmsterdamAges 16–70 - NCT07629583RecruitingPhase 1
Testing cevostamab for lupus with kidney involvement
This study tests a new drug called cevostamab for people with systemic lupus erythematosus (SLE), a condition where the immune system attacks the body's own tissues. Some participants also have lupus nephritis, which means the disease is affecting their kidneys. The drug may help by targeting a specific part of the immune system.
SevilleAges 18–75 - NCT07201129RecruitingPhase 3
Cenerimod for Active Lupus Nephritis
This trial tests if an investigational drug called cenerimod can safely and effectively treat active lupus nephritis when added to your regular lupus medications. It's for people with recent kidney biopsy showing active lupus kidney disease and high protein in urine.
Doral, FloridaAges 18–75 - NCT07719140RecruitingPhase 4
Lower steroid dose study for children with lupus nephritis
This trial tests whether a lower starting dose of steroids can control kidney inflammation in children with lupus nephritis. It aims to reduce side effects while still treating the disease effectively.
Beijing, Beijing MunicipalityAges 6–18 - NCT03543839RecruitingPhase 4
Belimumab for early lupus activity in the first two years
This trial tests belimumab to see if it can improve lupus (SLE) disease activity in people who were diagnosed within the last two years. You may be eligible if your lupus is currently mild to moderate and your background lupus medicines are stable.
Manhasset, New YorkAges 18 years+ - NCT04320680Recruiting
Study visits for adults with lupus in Brest, France
This study focuses on people aged 18 and older with lupus who attend a multi-team clinic visit in Brest, France. It mainly looks at whether you can participate in the multidisciplinary consultation and its related study procedures.
BrestAges 18–80 - NCT04702256RecruitingPhase 3
Treating lupus kidney inflammation with or without extra steroid tablets
This trial tests whether adding standard oral steroid tablets to mycophenolate helps lupus nephritis (inflammation of the kidneys) more than using obinutuzumab plus mycophenolate, without extra oral steroids. It may help find a treatment plan that controls active kidney disease while changing how much steroid is used.
ParisAges 14 years+ - NCT06044337Enrolling by invitationPhase 3
Long-term safety study of litifilimab for skin lupus
This study is a long-term follow-up for people who already completed a 52-week study of the study drug litifilimab for active skin lupus. It will check the safety of continued treatment and see if it keeps helping symptoms.
Birmingham, AlabamaAges 18 years+
Hear when a new Lupus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lupus?
- Yes. Clin2 currently lists 338 recruiting lupus studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lupus trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lupus trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.